Subcutaneous Implantable Defibrillator

play icon
EMBLEM™ S-ICD Torso Animation
play icon
The evolution of sudden cardiac death prevention
play icon
Over 100000 S-ICD patient implants across 70+ countries
play icon
EMBLEM™ S-ICD Torso Animation
As we stand at the threshold of a truly transformative change in how we provide therapy to patients at risk of cardiac arrhythmias, discover more about the evolution of sudden cardiac death prevention and how we are now looking forward to what patients are going to need in the next 5, 10, 15 years.
A patient’s perspective
S-ICD System Product Animation

The only extrathoracic device of its kind

The S-ICD system was designed to address the main complications that may occur in Transvenous ICDs: Lead Complications and Infection.1
More than 18 years of clinical data shows that the S-ICD is safe and effective and has comparable performance to TV-ICD in treating VT/VF.2,3
The S-ICD System leaves the heart and vasculature UNTOUCHED, avoiding the complications associated with transvenous leads.

Product Details

The EMBLEM MRI S-ICD protects patients from sudden cardiac death while avoiding the serious risks of more-invasive ICD options.4-10

More than 20 years of clinical data show us that S-ICD:

  • is safe and effective
  • is superior to TV-ICD showing lower and less severe lead-related complications
  • has a very low rate of inappropriate therapy
  • is suitable for all patients without the need for pacing


S-ICD is Recommended in both US and EU Guidelines

Guidance 2017 AHA/ACC/HRS Guidelines4 2015 ESC Guidelines For S-ICD patients...
Class I   With high risk of infection, including Diabetic patients (up to 35% of the ICS population)5
Class IIa Without need of pacing (CRT, bradycardia, ATP)
The 2017 Guidelines by the American Heart Association (AHA), American College of Cardiology (ACC), and the Heart Rhythm Society (HRS) include recommended use of the S-ICD for ICD indicated patients with high infection risk.


ATLAS Result: S-ICD is superior to TV-ICD 10



The EMBLEM™ S-ICD has proven superiority to TV-ICD in preventing the serious complications associated with invasive leads as early as 6 months after implant, as shown in the ATLAS trial.


Symposium – The S-ICD: Ask Me Anything

with Lucas Boersma